pharmacokinetics poloxamer sustained release in vitro release sd, standard deviation im, intramuscular atp, adenosine 5′ triphosphate auc80h, area under the analyte concentration versus time curve from time zero to 80 h auclast, area under the analyte concentration versus time curve from time zero to the time of the last measurable (non-below quantification level) concentration auc∞, area under the analyte concentration vs time curve from time zero to infinite time c0, analyte plasma concentration at time zero can, acetonitrile cmc, critical micellar concentration cmt, critical micellar temperature cmax, maximum observed analyte plasma concentration dn, dose normalized doe, design of experiments eo, ethylene oxide gpt, gel point temperature gel erosion h&e, hematoxylin and eosin iv, intravenous in situ forming gels k2.edta, potassium ethylenediaminetetraacetic acid lc–ms/ms, liquid chromatography-tandem mass spectrometry mdr-tb, multi-drug resistant tuberculosis mrm, multiple reaction monitoring nmp, n-methyl-2-pyrrolidone p338, poloxamer 338 p407, poloxamer 407 plga, poly-(dl-lactic-co-glycolic acid) po, propylene oxide tfa, trifluoroacetic acid uhplc, ultra-high performance liquid chromatography uv, ultraviolet n, sample size t1/2, apparent terminal elimination half-life tlast, sampling time until the last measurable (non-below quantification level) analyte plasma concentration tmax, sampling time to reach the maximum observed analyte plasma concentration